Faruqi & Faruqi Investigates Neumora Therapeutics for Potential Securities Law Violations.
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 25, 2023
NEW YORK, NY / ACCESSWIRE / April 19, 2023 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NRXP) of the pending class action lawsuit.
The lawsuit is brought on behalf of all persons and entities that purchased or acquired Neumora's securities between January 27, 2023, and March 14, 2023, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Neumora's alleged violations of federal securities laws.
On March 14, 2023, Neumora issued a press release announcing its withdrawal of its investigational new drug (IND) application for its lead product candidate, NM-01, due to a request from the U.S. Food and Drug Administration (FDA) to provide additional information. On this news, Neumora's stock price fell significantly, causing significant losses to investors.
The lawsuit alleges that Neumora and certain of its officers and directors made false and/or misleading statements and/or failed to disclose material information, including that the Company's IND application was incomplete and/or misleading, and that the FDA was unlikely to approve the application as filed.
The lead plaintiff deadline for this lawsuit is April 25, 2023. Investors who purchased or acquired Neumora securities during the Class Period and suffered losses are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal rights and options.
Faruqi & Faruqi, LLP is a leading national securities law firm with extensive experience in prosecuting securities class actions. The firm is committed to providing outstanding service to its clients, and its experienced attorneys are dedicated to ensuring that clients receive the compensation they deserve.
Contact: Richard Gonnello or Michael Perlmutter Faruqi & Faruqi, LLP r Gonell@faruqilaw.com or m Perlmutter@faruqilaw.com (877) 247-4292 or (212) 983-9331 SOURCE: Faruqi & Faruqi, LLP